Nektar Therapeutics (NKTR) EBT Growth (1y) (2011 - 2026)
Powered by 
Analysis
Nektar Therapeutics (NKTR) EBT Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 88.92% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 6.23% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 213.87% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 530.43% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -12.04% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 96.45% |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | -2.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.30% |
| Mar 31, 2026 | 7.07% |
| Dec 31, 2025 | -595.60% |
| Sep 30, 2025 | 5.47% |
| Jun 30, 2025 | 24.70% |
| Mar 31, 2025 | -25.88% |
| Dec 31, 2024 | 116.63% |
| Sep 30, 2024 | 19.28% |
| Jun 30, 2024 | -2.24% |
| Mar 31, 2024 | 73.13% |
| Dec 31, 2023 | 33.65% |
| Sep 30, 2023 | 22.47% |
| Jun 30, 2023 | 67.81% |
| Mar 31, 2023 | -51.86% |
| Dec 31, 2022 | 56.77% |
| Sep 30, 2022 | 54.32% |
| Jun 30, 2022 | -27.01% |
| Mar 31, 2022 | 26.54% |
| Dec 31, 2021 | -25.40% |
| Sep 30, 2021 | -19.37% |